HCW Biologics is trading at $1.33, down 10.13% on October 13, 2026; no clear announcement explains the decline.
- October 9 company news described FDA guidance for preparing an IND application; filing remains targeted for the first half of 2027—not a new negative development.
- Biotech shares were weak, with XBI down 2.01%.
- A prior filing registered up to 1.81 million shares for resale by holders, but available sources do not establish it drove the decline.